CTLA4 and melanoma: At present, antibodies targeting the cell surface programmed cell death 1 (PD-1) receptor (nivolumab or pembrolizumab), either in monotherapy or in combination with an antibody against the cytotoxic T-lymphocyte antigen-4 (CTLA-4) (ipilimumab), are the standard of care for melanoma patients [78].